csirt@kutim:~/threat-intel/cve/CVE-2026-100720

Katalog CVE

CVSS 8.7 · High EPSS 0,22%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting'). Skor CVSS 3.1 8.7 (High) menurut vulncheck.com.

Deskripsi (NVD)

Froxlor 2.0.0 through 2.3.10 is vulnerable to stored cross-site scripting. When a customer (the lowest-privileged authenticated role) uploads an SSL certificate for one of their own domains, the Certificates API add()/update() methods parse it with openssl_x509_parse() and store the issuer organization (issuer['O']) value verbatim without sanitization. Froxlor's table-listing renderer then emits scalar cells through Twig's `raw` filter, disabling HTML auto-escaping, so when an administrator or reseller opens Domains > SSL certificates the attacker-supplied issuer value executes as script in the privileged user's session. This crosses a privilege boundary from customer to admin and can result in full administrator account takeover; because a Froxlor admin controls webserver, DNS, and PHP configuration applied by a cron job running as root, the issue can be further escalated to command execution as root on the managed server. The issue is fixed in Froxlor 2.3.12.

Rincian

Terbit di NVD
26 September 2026
Terakhir diubah
26 September 2026
Status NVD
Deferred
CVSS 3.1
8.7 (High), sumber vulncheck.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:H/I:H/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,22% peluang dieksploitasi; lebih tinggi dari 11,0% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.